Positive News SentimentPositive NewsNASDAQ:ALXO ALX Oncology (ALXO) Stock Price, News & Analysis $0.58 -0.05 (-7.35%) Closing price 04:00 PM EasternExtended Trading$0.59 +0.01 (+1.55%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ALX Oncology Stock (NASDAQ:ALXO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ALX Oncology alerts:Sign Up Key Stats Today's Range$0.56▼$0.6350-Day Range$0.41▼$0.6352-Week Range$0.40▼$6.02Volume1.24 million shsAverage Volume759,344 shsMarket Capitalization$30.97 millionP/E RatioN/ADividend YieldN/APrice Target$3.30Consensus RatingModerate Buy Company Overview ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California. Read More ALX Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreALXO MarketRank™: ALX Oncology scored higher than 77% of companies evaluated by MarketBeat, and ranked 255th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingALX Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageALX Oncology has only been the subject of 2 research reports in the past 90 days.Read more about ALX Oncology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ALX Oncology are expected to grow in the coming year, from ($2.76) to ($2.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ALX Oncology is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ALX Oncology is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioALX Oncology has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about ALX Oncology's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.41% of the float of ALX Oncology has been sold short.Short Interest Ratio / Days to CoverALX Oncology has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in ALX Oncology has recently decreased by 10.48%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldALX Oncology does not currently pay a dividend.Dividend GrowthALX Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.41% of the float of ALX Oncology has been sold short.Short Interest Ratio / Days to CoverALX Oncology has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in ALX Oncology has recently decreased by 10.48%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News SentimentN/A News SentimentALX Oncology has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ALX Oncology this week, compared to 2 articles on an average week.Search Interest6 people have searched for ALXO on MarketBeat in the last 30 days. MarketBeat Follows2 people have added ALX Oncology to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ALX Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,564.00 in company stock.Percentage Held by Insiders21.00% of the stock of ALX Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.97% of the stock of ALX Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ALX Oncology's insider trading history. Receive ALXO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address ALXO Stock News HeadlinesALX Oncology Holdings Inc. (ALXO) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comALX Oncology to Present at the Jefferies 2025 Global Healthcare ConferenceMay 30, 2025 | globenewswire.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.July 29 at 2:00 AM | Timothy Sykes (Ad)ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast EventMay 20, 2025 | globenewswire.comALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025May 13, 2025 | globenewswire.comALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | finance.yahoo.comALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | globenewswire.com3ALXO : What's Next: ALX Oncology Holdings's Earnings PreviewMay 7, 2025 | benzinga.comSee More Headlines ALXO Stock Analysis - Frequently Asked Questions How have ALXO shares performed this year? ALX Oncology's stock was trading at $1.67 at the beginning of 2025. Since then, ALXO shares have decreased by 65.3% and is now trading at $0.58. How were ALX Oncology's earnings last quarter? ALX Oncology Holdings Inc. (NASDAQ:ALXO) issued its earnings results on Thursday, May, 8th. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by $0.11. When did ALX Oncology IPO? ALX Oncology (ALXO) raised $128 million in an initial public offering (IPO) on Friday, July 17th 2020. The company issued 8,000,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor acted as the underwriters for the IPO and LifeSci Capital was co-manager. How do I buy shares of ALX Oncology? Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ALX Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that ALX Oncology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), Broadcom (AVGO) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/08/2025Today7/29/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALXO CIK1810182 Webwww.alxoncology.com Phone650-466-7125FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for ALX Oncology$3.30 High Price Target$9.00 Low Price Target$1.00 Potential Upside/Downside+469.0%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$134.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-104.43% Return on Assets-77.74% Debt Debt-to-Equity Ratio0.09 Current Ratio5.47 Quick Ratio5.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.14 per share Price / Book0.27Miscellaneous Outstanding Shares53,396,000Free Float42,183,000Market Cap$30.97 million OptionableOptionable Beta1.11 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ALXO) was last updated on 7/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.